
    
      Participants who had a good or moderate European League Against Rheumatism (EULAR) response
      but not achieve remission at the end of Part 1 were invited to participate in Part 2 and were
      randomized to either intravenous golimumab (IV GLM) + subcutaneous golimumab (SC GLM) or SC
      GLM alone.
    
  